TW201805003A - Pharmaceutical solid dispersion of a BCL-2 inhibitor, pharmaceutical compositions thereof, and uses for the treatment of cancer - Google Patents

Pharmaceutical solid dispersion of a BCL-2 inhibitor, pharmaceutical compositions thereof, and uses for the treatment of cancer Download PDF

Info

Publication number
TW201805003A
TW201805003A TW106122603A TW106122603A TW201805003A TW 201805003 A TW201805003 A TW 201805003A TW 106122603 A TW106122603 A TW 106122603A TW 106122603 A TW106122603 A TW 106122603A TW 201805003 A TW201805003 A TW 201805003A
Authority
TW
Taiwan
Prior art keywords
cancer
pharmaceutical composition
oral administration
pharmaceutical
solid dispersion
Prior art date
Application number
TW106122603A
Other languages
Chinese (zh)
Inventor
卡洛琳 雀敏
珍-曼紐 皮恩
戴雅 柏瑪
優利奇 密爾
艾默利克 瑞勞德
Original Assignee
施維雅藥廠
諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 施維雅藥廠, 諾華公司 filed Critical 施維雅藥廠
Publication of TW201805003A publication Critical patent/TW201805003A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Abstract

This invention relates to pharmaceutical solid dispersion formulations of Compound A: and the use of theses formulations for treating cancer.

Description

BCL-2抑制劑之醫藥固體分散物、其醫藥組合物及用於治療癌症之用途Pharmaceutical solid dispersion of BCL-2 inhibitor, its pharmaceutical composition and use for treating cancer

本發明係關於固體分散醫藥中間體，其包含N -(4-羥基苯基)-3-{6-[((3S )-3-(4-嗎啉基甲基)-3,4-二氫-2(1H )-異喹啉基)羰基]-1,3-苯并二氧雜環戊烯-5-基}-N -苯基-5,6,7,8-四氫-1-吲嗪甲醯胺(在本文中稱為「化合物A」)或其醫藥上可接受之鹽，及包含該固體分散醫藥中間體之用於經口投與之醫藥組合物。本發明亦關於此等組合物用於治療癌症、免疫系統疾病及自體免疫疾病之用途。 化合物A之化學結構係：

Figure TW201805003AD00001
其製備、其作為治療癌症之Bcl-2抑制劑之用途及其醫藥調配物闡述於WO 2013/110890 (實例1)中，其內容係以引用方式併入本文中。呈鹽酸鹽形式之化合物A (「化合物A.HCl」)之製備明確地揭示於此文件中。呈游離鹼或其鹽酸鹽形式之化合物A係水溶性較差之藥物，即其溶解度在酸性及中性pH下低於0.1 mg/mL，此對口服生物利用度及治療效應具有挑戰。將其歸類為BCS II (低溶性且高滲透性)原料藥，由此其吸收僅受其溶解度限制。對於多種鹽形式而言，在犬、大鼠及小鼠中所觀測到之低的活體內暴露係此參數之直接結果。 需要開發在化學上及在物理上穩定之組合物，其與標準錠劑調配物相比，可提供增加之藥物暴露(增加之化合物A生物利用度)，以降低PK可變性並最佳化患者之投藥，例如錠劑負荷。亦期望提供組合物，其特徵使其能在無製造處理複雜性下製造。 本發明係關於化合物A之固體分散醫藥中間體及包含此等固體分散醫藥中間體之醫藥組合物，其能夠增加藥物暴露。其具有自任何適宜製程製備之化合物A開始獲得之益處，其中化合物A可以游離分子或與醫藥上可接受之酸或鹼之加成鹽存在。在一個實施例中，將化合物A與所選聚合物一起溶解於一種溶劑或溶劑之混合物中，容許獲得成分之完全溶解，且然後將所得溶液噴霧乾燥並蒸發出溶劑。替代之適宜製造技術包括溶劑蒸發、捏合、熔融凍凝及共沈澱。The present invention relates to a solid dispersion pharmaceutical intermediate, which contains N- (4-hydroxyphenyl) -3- {6-[((3 S ) -3- (4-morpholinylmethyl) -3,4- Dihydro-2 (1 H ) -isoquinolinyl) carbonyl] -1,3-benzodioxol-5-yl} -N -phenyl-5,6,7,8-tetrahydro -1-Indazine carboxamide (referred to herein as "Compound A") or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for oral administration containing the solid dispersed pharmaceutical intermediate. The invention also relates to the use of these compositions for the treatment of cancer, immune system diseases and autoimmune diseases. The chemical structure of Compound A is:
Figure TW201805003AD00001
Its preparation, its use as a Bcl-2 inhibitor for the treatment of cancer, and its pharmaceutical formulations are described in WO 2013/110890 (Example 1), the contents of which are incorporated herein by reference. The preparation of Compound A ("Compound A. HCl") in the form of the hydrochloride salt is clearly disclosed in this document. Compound A in the form of a free base or its hydrochloride is a poorly water-soluble drug, ie, its solubility is less than 0.1 mg / mL at acidic and neutral pH, which poses challenges for oral bioavailability and therapeutic effects. It is classified as a BCS II (low solubility and high permeability) API, so its absorption is limited only by its solubility. For many salt forms, the low in vivo exposure observed in dogs, rats, and mice is a direct result of this parameter. There is a need to develop chemically and physically stable compositions that can provide increased drug exposure (increased Compound A bioavailability) compared to standard lozenge formulations to reduce PK variability and optimize patients Administration, such as lozenge load. It is also desirable to provide compositions whose characteristics enable them to be manufactured without the complexity of manufacturing processes. The present invention relates to a solid dispersed pharmaceutical intermediate of Compound A and a pharmaceutical composition containing these solid dispersed pharmaceutical intermediates, which can increase drug exposure. It has the benefits obtained from Compound A prepared by any suitable process, wherein Compound A may exist as a free molecule or as an addition salt with a pharmaceutically acceptable acid or base. In one embodiment, Compound A and the selected polymer are dissolved in a solvent or mixture of solvents, allowing complete dissolution of the ingredients, and then the resulting solution is spray dried and the solvent is evaporated. Alternative suitable manufacturing techniques include solvent evaporation, kneading, melt freezing and co-precipitation.

如本文中所使用之術語「固體分散醫藥中間體」意指分散於聚合固體基質載劑中之非晶形原料藥。意欲將此形式之中間體調配成呈醫藥劑型形式之醫藥組合物，以促進原料藥在胃腸道中之溶解並使藥物維持在過飽和狀態以被吸收。固體分散醫藥中間體係藉由業內已知之技術產生，該等技術係例如噴霧乾燥、溶劑蒸發、捏合、共沈澱、熱熔融擠出及熔融凍凝。 如本文中所使用之術語「固體分散聚合物」意指適於以可再現及工業上可行之方式獲得呈非晶型之原料藥之穩定固體分散物的聚合物或其聚合物之混合物。原料藥分子分佈於防止其形成晶格之固體基質中。根據本發明可使用以下固體分散聚合物：(i)乙烯基聚合物，包括聚乙烯酯(例如聚酞酸乙酸乙烯酯)以及基於聚乙烯基吡咯啶酮之均聚物及共聚物(例如聚乙烯基吡咯啶酮(PVP，例如可自BASF獲得之PVP K30)及共聚維酮(即乙烯基吡咯啶酮-乙酸乙烯酯共聚物，例如可由BASF獲得之Kollidon® VA64))及聚乙烯基己內醯胺-聚乙酸乙烯酯-聚乙二醇接枝共聚物(例如可自BASF獲得之Soluplus®)；(ii)纖維素化合物，包括纖維素醚或酯，例如甲基纖維素(MC)、羥丙基甲基纖維素(HPMC)及羥丙基纖維素(HPC)化合物及更尤其HPMC E5 (例如可自Dow獲得之Methocel® E5)、HPMC E15 (其可自Ashland獲得)、HPMC-3CPS (其可自Dow獲得)、Klucel® EF (其係HPC且可自Ashland獲得)、HPMC乙酸琥珀酸酯(HPMC-AS) (例如可自Shi-Etsu獲得之Aqoat®)或HPMC酞酸酯(HPMC-P，其可自ShinEtsu獲得)；(iii)聚甲基丙烯酸酯或甲基丙烯酸之共聚物，其對應於甲基丙烯酸及丙烯酸酯或甲基丙烯酸酯之完全聚合之共聚物(例如可自Evonik獲得之Eudragit®)。 可將本發明之固體分散醫藥中間體與一或多種其他醫藥上可接受之非活性成分(通常亦稱為醫藥賦形劑，例如填充劑、崩解劑、潤滑劑、助流劑)一起調配，以形成用於經口投與之醫藥組合物。 「x90粒徑」意指對應於90%之累計篩下分佈之顆粒尺寸。舉例而言，可使用鐳射光繞射實施測試。 填充劑為熟練調配者所熟知。可選填充劑包括乳糖、甘露醇(例如，適於直接製錠之甘露醇DC)、山梨醇、葡萄糖、右旋糖、碳酸鈣、磷酸鈣、羥丙基甲基纖維素(HPMC)及微晶纖維素(纖維素MK GR)。 崩解劑為熟練調配者所熟知。通常可選之崩解劑包括交聯羧甲基纖維素鈉(Na-CMC XL，亦稱為「鈉(natrium)-CMC XL」或「鈉(sodium)-CMC-XL」或「交聯羧甲基纖維素鈉(croscarmellose sodium)」)、澱粉或經改質澱粉(例如，羥乙酸澱粉鈉、玉米澱粉)及交聚維酮(即交聯聚乙烯吡咯啶酮，例如可自Ashland獲得之Plasdone XL10)。 潤滑劑為熟練調配者所熟知。通常可選之潤滑劑包括硬脂酸、硬脂酸鎂、硬脂醯富馬酸鹽、滑石、山崳酸甘油酯及蓖麻油。 助流劑為熟練調配者所熟知。通常可選之助流劑包括二氧化矽(例如，可自Evonik獲得之Aerosil® 200)、硬脂酸鎂、滑石。 術語「用於經口投與之醫藥組合物」意指(例如)錠劑或膠囊、尤其錠劑。此錠劑可視情況經膜包衣。 「化合物A.HCl」或「化合物A.HCl鹽」意指N -(4-羥基苯基)-3-{6-[((3S )-3-(4-嗎啉基甲基)-3,4-二氫-2(1H )-異喹啉基)羰基]-1,3-苯并二氧雜環戊烯-5-基}-N -苯基-5,6,7,8-四氫-1-吲嗪甲醯胺之鹽酸鹽。 如本文所用術語「包含」意指「包括」，且除非上下文另外表明，例如當組分一起總計100%時，否則其並不意欲排除任何額外組分之存在。 術語「溶劑」意指能夠溶解化合物A及所選聚合物之溶劑。較佳者將係：(i)極性質子溶劑，例如醇及更尤其甲醇及乙醇；(ii)非極性質子溶劑，例如丙酮及二氯甲烷；(iii)彼等溶劑之混合物；或(iv)彼等溶劑與水之混合物。 「癌症」意指其中細胞之群展示不受控生長之一類疾病。癌症類型包括血液癌(淋巴瘤及白血病)及實體腫瘤，包括癌瘤、肉瘤或母細胞瘤。「癌症」包括膀胱癌、腦癌、乳癌及子宮癌、慢性淋巴性白血病、結腸直腸癌、食道癌及肝癌、淋巴母細胞性白血病、非霍奇金氏淋巴瘤(non-Hodgkin lymphomas)、黑色素瘤、惡性血液病、骨髓瘤、卵巢癌、非小細胞肺癌、前列腺癌及小細胞肺癌。 「游離分子」及「游離鹼」可在本文中互換使用且在不呈鹽形式時係指化合物A。本發明之實施例 下文闡述本發明之多個實施例。 E1. 固體分散醫藥中間體，其包含呈游離分子或醫藥上可接受之鹽形式之N -(4-羥基苯基)-3-{6-[((3S )-3-(4-嗎啉基甲基)-3,4-二氫-2(1H )-異喹啉基)羰基]-1,3-苯并二氧雜環戊烯-5-基}-N -苯基-5,6,7,8-四氫-1-吲嗪甲醯胺(化合物A)，及一或多種固體分散聚合物。 E2. 如實施例1之固體分散醫藥中間體，其包含10重量%至60重量%之化合物A游離分子或醫藥上可接受之鹽。 E3. 如實施例2之固體分散醫藥中間體，其包含20重量%至50重量%之化合物A游離分子或醫藥上可接受之鹽。 E4. 如實施例3之固體分散醫藥中間體，其包含35重量%至45重量%、較佳40重量%之化合物A游離分子或醫藥上可接受之鹽。 E5. 如實施例1、2、3或4中任一者之固體分散醫藥中間體，其包含化合物A.HCl鹽。 E6. 如實施例1至5中任一者之固體分散醫藥中間體，其包含選自以下各項之固體分散聚合物：聚乙烯基己內醯胺-聚乙酸乙烯酯-聚乙二醇接枝共聚物(例如，Soluplus®)、聚乙烯基吡咯啶酮K30 (PVP K30)、羥丙基甲基纖維素E5 (HPMC E5)、羥丙基纖維素(例如，Klucel® EF)、羥丙基甲基纖維素乙酸琥珀酸酯(例如，Aqoat®)及共聚維酮(例如，Kollidon® VA64)，較佳地固體分散聚合物選自聚乙烯基吡咯啶酮K30 (PVP K30)、羥丙基甲基纖維素E5 (HPMC E5)、羥丙基甲基纖維素乙酸琥珀酸酯(Aqoat®)及共聚維酮(例如，Kollidon® VA64)，更佳地固體分散聚合物選自聚乙烯基吡咯啶酮K30 (PVP K30)、羥丙基甲基纖維素乙酸琥珀酸酯(Aqoat®)及共聚維酮(Kollidon® VA64)。 E7. 如實施例6之固體分散醫藥中間體，其包含一種固體分散聚合物，其係共聚維酮(Kollidon® VA64)或羥丙基甲基纖維素乙酸琥珀酸酯(Aqoat®)。 E8. 如實施例7之固體分散醫藥中間體，其包含一種固體分散聚合物，其係共聚維酮(Kollidon® VA64)。 E9. 如實施例8之固體分散醫藥中間體，其包含約60重量%之共聚維酮(Kollidon® VA64)。 E10. 如實施例1至9中任一者之固體分散醫藥中間體，其係藉由噴霧乾燥製程製造。 E11. 用於經口投與之醫藥組合物，其包含總組合物之10重量%至80重量%、尤其10重量%至50重量%之量之如實施例1至10中任一者之固體分散醫藥中間體。 E12.如實施例11之用於經口投與之醫藥組合物，其包含總組合物之20重量%至30重量%、尤其22重量%至26重量%之量之固體分散醫藥中間體。 E13. 如實施例11或12之用於經口投與之醫藥組合物，其包含至少一種選自以下之填充劑：乳糖、甘露醇、碳酸鈣、磷酸鈣、羥丙基甲基纖維素(HPMC)及微晶纖維素(纖維素MK GR)。 E14. 如實施例11、12或13之用於經口投與之醫藥組合物，其包含一或多種填充劑，填充劑之總量為總組合物之10重量%至90重量%、尤其30重量%至90重量%、更特定而言55重量%至67重量%。 E15. 如實施例11至14中任一者之用於經口投與之醫藥組合物，其包含甘露醇及纖維素MK GR二者。 E16. 如實施例11至15中任一者之用於經口投與之醫藥組合物，其包含總組合物之5重量%至50重量%、尤其20重量%至45重量%、更特定而言30重量%至35重量%之量之甘露醇。 E17. 如實施例11至16中任一者之用於經口投與之醫藥組合物，其包含總組合物之5重量%至50重量%、尤其20重量%至40重量%、更特定而言30重量%至35重量%之量之纖維素MK GR。 E18. 如實施例11至17中任一者之用於經口投與之醫藥組合物，其包含甘露醇及纖維素MK GR二者，其中甘露醇係以總組合物之20重量%至45重量%之量存在，且纖維素MK GR係以20重量%至40重量%之量存在。 E19. 如實施例11至18中任一者之用於經口投與之醫藥組合物，其包含： a. 30重量%至35重量%之量之甘露醇，及 b. 30重量%至35重量%之量之纖維素MK GR。 E20. 如實施例11至19中任一者之用於經口投與之醫藥組合物，其中該組合物包含至少一種選自以下各項之崩解劑：交聯羧甲基纖維素鈉(Na-CMC XL)、羥乙酸澱粉鈉、玉米澱粉及交聚維酮(Plasdone XL10)。 E21. 如實施例11至20中任一者之用於經口投與之醫藥組合物，其包含3重量%至20重量%之量之崩解劑。 E22. 如實施例21之用於經口投與之醫藥組合物，其包含7重量%至13重量%、尤其10重量%之量之崩解劑。 E23. 如實施例20至22中任一者之用於經口投與之醫藥組合物，其中該崩解劑係交聯羧甲基纖維素鈉(鈉-CMC XL)。 E24. 如實施例11至23中任一者之用於經口投與之醫藥組合物，其包含至少一種助流劑。 E25. 如實施例24之用於經口投與之醫藥組合物，其中助流劑之總量係以0.1重量%至5重量%之量存在。 E26. 如實施例25之用於經口投與之醫藥組合物，其包含0.2重量%至0.8重量%之量之助流劑。 E27. 如實施例24至26中任一者之用於經口投與之醫藥組合物，其包含一種助流劑，其係二氧化矽(例如Aerosil 200)。 E28. 如實施例11至27中任一者之用於經口投與之醫藥組合物，其中該組合物包含潤滑劑。 E29. 如實施例28之用於經口投與之醫藥組合物，其中該組合物包含選自以下各項之潤滑劑：硬脂酸、硬脂酸鎂、硬脂醯富馬酸鹽、滑石、山崳酸甘油酯及蓖麻油。 E30. 如實施例29之用於經口投與之醫藥組合物，其包含一種潤滑劑，其係硬脂酸鎂。 E31. 如實施例28至30中任一者之用於經口投與之醫藥組合物，其包含至少一種0.1重量%至5重量%、尤其0.5重量%至1.5重量%之量之潤滑劑。 E32. 如實施例11至31中任一者之用於經口投與之醫藥組合物，其呈錠劑形式，視情況經膜包衣。 E33. 如實施例11至32中任一者之用於經口投與之醫藥組合物，其包含5 mg至150 mg、尤其25 mg、50 mg、75 mg及100 mg化合物A游離分子。 E34. 用於經口投與之醫藥組合物，其包含： ● 如實施例1至10中任一者之固體分散醫藥中間體，及 ● 選自甘露醇DC及乳糖之填充劑。 E35. 如實施例34之醫藥組合物，其係包含以下之錠劑： ● 如實施例1至10中任一者之固體分散醫藥中間體，及 ● 選自甘露醇DC及乳糖之填充劑。 E36. 如實施例35之醫藥組合物，其係包含以下之錠劑： ● 如實施例1至10中任一者之固體分散醫藥中間體，及 ● 甘露醇DC。 E37. 如實施例34之醫藥組合物，其係包含以下之錠劑： ● 如實施例1至10中任一者之固體分散醫藥中間體， ● 甘露醇DC及 ● 交聯羧甲基纖維素鈉(鈉CMC XL)。 E38. 如實施例35至37中任一者之用於經口投與之錠劑，其包含5 mg至150 mg、尤其25 mg、50 mg、75 mg及100 mg化合物A游離分子。 E39. 調節個體中Bcl-2受體活性之方法，其中該方法包含向個體投與治療有效量之如實施例11至38中任一者之組合物。 E40. 治療選自癌症、免疫系統疾病及自體免疫疾病之病症或疾病之方法，其包含向個體投與治療有效量之如實施例11至38中任一者之組合物。 E41. 如實施例40之方法，其中該癌症選自膀胱癌、腦癌、乳癌及子宮癌、慢性淋巴性白血病、結腸直腸癌、食道癌及肝癌、淋巴母細胞性白血病、非霍奇金氏淋巴瘤、黑色素瘤、惡性血液病、骨髓瘤、卵巢癌、非小細胞肺癌、前列腺癌及小細胞肺癌。 E42. 如實施例11至38中任一者之醫藥組合物，其用作藥劑。 E43. 如實施例11至38中任一者之醫藥組合物，其用於治療選自癌症、免疫系統疾病及自體免疫疾病之病症或疾病。 E44. 如實施例11至38中任一者之醫藥組合物，其用於治療癌症，其中癌症選自膀胱癌、腦癌、乳癌及子宮癌、慢性淋巴性白血病、結腸直腸癌、食道癌及肝癌、淋巴母細胞性白血病、非霍奇金氏淋巴瘤、黑色素瘤、惡性血液病、骨髓瘤、卵巢癌、非小細胞肺癌、前列腺癌及小細胞肺癌。 E45. 組合，其包含： ● 如實施例11至38中任一者之醫藥組合物，及 ● 同時、依序或分開使用之一或多種治療活性劑。 E46. 一種製備如實施例1至10中任一者之固體分散醫藥中間體之方法，其包含以下步驟：(i)將化合物A或其醫藥上可接受之鹽與固體分散聚合物在一或多種溶劑中混合，(ii)將所得溶液噴霧乾燥，及(iii)蒸發出溶劑。 E47. 一種製備如實施例1至10中任一者之固體分散醫藥中間體之方法，其係由以下組成：(i)將化合物A或其醫藥上可接受之鹽與固體分散聚合物在一或多種溶劑中混合，(ii)將所得溶液噴霧乾燥，及(iii)蒸發出溶劑。 E48. 如實施例46或47之方法，其中溶劑係甲醇/丙酮之混合物或甲醇/二氯甲烷之混合物。 E49. 如實施例1至10中任一者之固體分散醫藥中間體，其中固體分散醫藥中間體之x90粒徑係20微米至35微米。 另一實施例提供如本文實施例中任一者之用於經口投與之醫藥組合物，其中該組合物視情況包含選自以下之表面活性劑：泊洛沙姆(poloxamer，例如Kolliphor P188 (其可自BASF獲得))、十二烷基硫酸鈉、聚山梨醇酯80 (Tween 80)、Tween 20、聚氧乙烯35 (Polyoxyl 35)氫化蓖麻油(例如Kolliphor® ELP (其可自BASF獲得))。 另一實施例提供如本文實施例中任一者之用於經口投與之醫藥組合物，其中該組合物視情況包含選自以下之黏合劑：聚維酮(例如PVP K30)、麥芽糊精(例如來自Roquette之例如Lycatab® DSH)、HPMC (例如來自Shin-Etsu之例如Pharmacoat® 606)及HPC (例如HPC-L)。 另一實施例提供如本文實施例中任一者之用於經口投與之醫藥組合物，其中該組合物視情況包含膜包衣。 錠劑膜包衣係本發明之可選實施例。其可經選擇以防止濕氣攝取及/或磨損，並在活性原料藥與外部環境之間提供物理障壁。熟練調配者可根據業內所熟知者選擇適當膜包衣。舉例而言，可使用基於HPMC或PVA之包衣，例如Opadry® (基於HPMC)、Opadry II® (基於PVA)及OpadryAMB II® (基於PVA)。 可使用本文中所闡述之固體分散醫藥中間體來提供能夠使化合物A之生物利用度增加之組合物。此外，已令人驚訝地發現本發明之某些實施例提供額外優點。舉例而言，當在固體分散醫藥中間體中使用以下聚合物時：聚乙烯基己內醯胺-聚乙酸乙烯酯-聚乙二醇接枝共聚物(Soluplus®)、聚乙烯基吡咯啶酮(PVP K30)、羥丙基甲基纖維素(HPMC E5)、HPC (Klucel® EF)、HPMC乙酸琥珀酸酯(Aqoat®)或乙烯基吡咯啶酮-乙酸乙烯酯共聚物(Kollidon® VA64)，觀測到低比率之降解且無化合物A之結晶，且特定而言對於聚乙烯基吡咯啶酮(PVP K30)、羥丙基甲基纖維素(HPMC E5)、HPC (Klucel® EF)、HPMC乙酸琥珀酸酯(Aqoat®)或乙烯基吡咯啶酮-乙酸乙烯酯共聚物(Kollidon® VA64)。此外，聚合物聚乙烯基己內醯胺-聚乙酸乙烯酯-聚乙二醇接枝共聚物(Soluplus®)、聚乙烯基吡咯啶酮(PVP K30)、羥丙基甲基纖維素(HPMC E5)、HPMC乙酸琥珀酸酯(Aqoat®)及乙烯基吡咯啶酮-乙酸乙烯酯共聚物(Kollidon® VA64)能夠在大鼠中高度暴露，特別係聚乙烯基吡咯啶酮(PVP K30)、羥丙基甲基纖維素(HPMC E5)、HPMC乙酸琥珀酸酯(Aqoat®)及乙烯基吡咯啶酮-乙酸乙烯酯共聚物(Kollidon® VA64)。 對於本文中所闡述之包含固體分散醫藥中間體之醫藥組合物而言，已發現某些組分或組分之量提供意外益處。 如本文實施例中所闡述，當以約1:1之比率使用甘露醇及纖維素填充劑時，鑑別出另一意外優點。此等比率改良組合物之流動性，從而減少或避免膠凝。膠凝可使製造複雜化且亦可延緩化合物A之釋放。實例 實例 1 ：包含化合物 A.HCl 之固體分散醫藥中間體 組合物(重量%)： 化合物A.HCl鹽 40% Kollidon® VA64 60% 甲醇 在製造製程期間去除 丙酮 在製造製程期間去除製造製程 進料溶液之製備： 將甲醇(19.584 kg)及丙酮(19.584 kg)裝填至容器中且在室溫下攪動。添加化合物A.HCl (1 kg)並攪動混合物，直至溶液變得澄清為止。然後添加Kollidon ® VA64 (1.5 kg)並攪動混合物，直至溶液變得幾乎澄清為止。噴霧乾燥： 端視批量大小，可使用具有不同噴霧乾燥參數之不同設備將進料溶液噴霧乾燥。典型製程參數闡述於下文中： 裝置：Niro QSD3.6 噴霧乾燥：入口溫度90℃-180℃，出口溫度60℃-70℃ (目標65℃)，進給速率10-30 (kg/h)，製程氣體流速360 Kg/hr。裝置及噴霧乾燥參數可視需要修改。二級真空乾燥： 二級真空乾燥之典型參數：溫度60℃-70℃，乾燥壓力＜10 [mbar abs]，氮氣吹掃可選。 乾燥條件可隨批量大小而改變。舉例而言，對於較大批次，可部分地使用氮氣流在45℃至70℃在真空下乾燥固體分散物顆粒，直至滿足殘餘溶劑及水含量之規格為止。 自上文中所闡述之製程獲得之固體分散中間體之x90粒徑通常係20微米至35微米。實例 2 ：包含甘露醇之臨床服務調配物 2 ( 「 CSF2A 」 ) 錠劑 使用與實例8中所闡述相似之製造製程。實例 3 ：包含乳糖之錠劑 使用與實例8中所闡述相似之製造製程。實例 4 ：經口投與化合物 A.HCl 鹽後，經五肽胃泌素預處理之犬中之 PK 此研究之目標係在經五肽胃泌素預處理之雄性比格犬(Beagle dog)經口投用本文實例2及實例3之調配物之100 mg化合物A後，測定濃度-時程並評估化合物A.HCl鹽之藥物動力學參數。將實例2及3二者之錠劑用Opadry (HPMC)包衣用於此研究中。動物 雄性比格犬(n=4/處理/交叉設計) 在投藥之前使犬禁食＞15小時(過夜)。在投藥當天，在投藥後4小時後不久提供250 g-350 g食物(犬飲食：Art. Nr. 3353 Provimi Kliba SA，4303 Kaiseraugst，Switzerland)之每日部分。所有動物皆自由得到自來水。五肽胃泌素製備及向犬投藥 為降低胃中之pH並模擬人類酸性條件，在投與化合物A.HCl之前45分鐘，經由肌內途徑投與五肽胃泌素(6 µg/kg)。為製備溶液，將五肽胃泌素新溶解於PEG400中，然後在連續攪拌下添加水，以達成10% (v/v) PEG400溶液(PEG400:水，1:9，v:v)，其中最終五肽胃泌素濃度為80 µg/mL。使用23 G針肌內投藥體積為0.075 mL/kg。調配物及投藥 每次投藥時段之間之間歇期係至少3天。 調配物係藉由深喉施加總共100 mg化合物A/犬之4片錠劑來投與，隨後用20 mL飲用水沖洗。生物試樣之收集及處置 取樣概述 在下表中所呈現之時間點，自頭靜脈在經EDTA包覆之埃彭道夫管(Eppendorf tube)中收集血液(約1 mL/時間點)。收集後，立即將血液試樣置於冰上。收集後，將血液在15 min內離心(3000 g，10 min，4℃)。製備血漿並在-80℃下儲存，直至試樣分析測定為止。用於生物分析之試樣收集之時間表 EDTA：乙二胺四乙酸化合物 A 之量化 量測化合物A血漿濃度。使用20 µL血漿，化合物A之LLOQ (量化下限)係0.200 ng/mL。藥物動力學參數之數據評估 將濃度及藥物動力學參數(除Tmax及T末次以外)捨入至3個有效數位。藉助phoenix WinNonlin®軟體使用非分室化方法(WinNonlin，6.3版，Pharsight Corporation Mountain View，CA，USA)計算所有藥物動力學參數。藥物動力學結果 在交叉設計中處理所有犬，其中向每個動物單一經口投與標稱100 mg化合物A。在化合物A投藥之前45分鐘用五肽胃泌素預處理所有犬。化合物A之血漿濃度-時程顯示於圖1中。 投與實例3之組合物中之100 mg/犬之化合物A後，血漿暴露總計為27.1 ± 9.77 ng/mL/(mg/kg)之平均Cmax/劑量及86.1 ± 17.5 h·ng/mL/(mg/kg)之AUC末次/劑量。 投與實例2之組合物(CSF2A)中之100 mg/犬之化合物A後，血漿暴露總計為40.7 ± 24.3 ng/mL/(mg/kg)之平均Cmax/劑量及134 ± 55.3 h·ng/mL/(mg/kg)之平均AUC末次/劑量。 在投藥後1 h時對於所有調配物達到中值Tmax。 在犬中投與化合物A後，藉由變異係數(CV)評估之劑量正規化Cmax (Cmax/劑量)及劑量正規化AUC/末次(AUC末次/劑量)之動物間可變性分別在28.7%至59.7%及20.3%至41.3%之範圍內，此顯示在投用實例2之組合物(CSF2A)時最高之可變性。 高暴露係由實例2及3達成。然而，最高暴露係由在犬中具有較高可變性之折衷的實例2達成。實例 5 ：包含化合物 A.HCl 之替代固體分散醫藥中間體 已使用選自以下各項之群之聚合物製備不同固體分散醫藥中間體：Soluplus®、聚乙烯基吡咯啶酮K30 (PVP K30)、羥丙基甲基纖維素E5 (HPMC E5)、Klucel® EF、Aqoat® (HPMC AS-LF)及Kollidon® VA64。 組合物(重量%)： 化合物A.HCl鹽 30% 聚合物 70% 甲醇 在製造製程期間去除 二氯甲烷 在製造製程期間去除製造製程 在燒杯中稱重化合物A.HCl (3 g)及所選聚合物(7 g)。添加甲醇(100 mL)及二氯甲烷(100 mL)且在室溫下進行磁力攪拌，直至溶液變得澄清為止，此意味著化合物A.HCl及所選聚合物完全溶解。在50℃之出口溫度及8 mL/min之流速下將所得溶液噴霧乾燥。 並行地，使用不添加任何如下文所述聚合物之相似噴霧乾燥製程亦獲得非晶形化合物A. HCl： 在燒杯中稱重化合物A.HCl (10 g)。添加甲醇(150 mL)及二氯甲烷(150 mL)且在室溫下進行磁力攪拌，直至溶液變得澄清為止，此意味著化合物A.HCl完全溶解。在50℃之出口溫度及8 mL/min之流速下將所得溶液噴霧乾燥。實例 6 ：包含化合物 A.HCl 之固體分散醫藥中間體之物理及化學穩定性 將在實例5中所獲得之固體分散醫藥中間體以及經噴霧乾燥之化合物A. HCl (即無聚合物)儲存在變性之溫度及相對濕度條件下。在40℃/75% RH (相對濕度)及在50℃下儲存1個月後，使用HPLC/UV量測降解產物之比率。亦藉由X-射線繞射監測呈非晶型之固體分散醫藥中間體之物理穩定性。結果 對於所測試之所有聚合物，在40℃/ 75% RH下儲存1個月及在50℃下儲存1個月後，觀測到低比率之降解產物。此外，在先前條件下觀測到無結晶。在實例5中所獲得之固體分散醫藥中間體容許使呈非晶型之化合物A.HCl在變性儲存條件(即40℃/ 75% RH及50℃)下穩定1個月。實例 7 ：經口投與自於實例 6 中獲得之固體分散醫藥中間體製備之化合物 A.HCl 懸浮液後，大鼠中之 PK 此研究之目標係測定在經口投用100 mg/kg化合物A後，在大鼠中量測之藥物動力學參數。藉由將實例5之固體分散醫藥中間體溶解於純化水中之1% HEC (羥乙基纖維素)中製備懸浮液。動物及化合物 A.HCl 劑量值 將化合物A.HCl以100 mg/kg之劑量(以游離鹼表示)經口投與雄性Wistar大鼠(n=3/調配物，動物未禁食)。 以10 mL/kg之體積藉由胃管灌食對大鼠投藥。試樣 在投與後30 min、1 h、2 h、4 h、8 h及24 h時，將血液試樣(約0.1 mL)在室溫下自尾靜脈收集至肝素鈉管中。在每次抽取後，立即將血液離心以獲得血漿，並在-70℃或更低之溫度下在氣密密封塑膠管中冷凍儲存。分析 將試樣在室溫下解凍、渦旋混合並離心(5 min，4℃，3,000 rpm)。將等份(20 μL)試樣添加至含有20 μL於乙腈中之30.0 ng/mL Y 2202內標準品溶液之OSTRO板，然後添加150 µL乙腈。將板在室溫下以1,000 rpm混合1 min且在96孔板中溶析化合物。利用液相層析使用ESI+串聯質譜檢測(UPLC/MS-MS)分析試樣，其中量化限值= 0.1 ng/mL。藥物動力學結果 結果顯示大鼠中之暴露高且依賴於調配物。關於所獲得之AUC24 之最佳聚合物係Aqoat®及Kollidon® VA64，其次係PVP K30及HPMC E5，再次係Soluplus。對於所有調配物觀測到Tmax 在2h - 4h之範圍內。實例 8 ：臨床服務調配物 2 ( 「 CSF2B 」 ) 錠劑 組合物/無膜包衣之錠劑(重量/錠劑之重量%)： 來自實例1之固體分散醫藥中間體 24.6328% 甘露醇DC (填充劑) 31.9336% 纖維素MK GR (填充劑) 31.9336% 鈉-CMC XL (崩解劑) 10.0000% Aerosil 200 (助流劑) 0.5000% 硬脂酸鎂 (潤滑劑) 1.0000% 組合物/具有膜包衣之錠劑(重量/錠劑之重量%)： 來自實例1之固體分散醫藥中間體 23.7425% 甘露醇DC (填充劑) 30.7794% 纖維素MK GR (填充劑) 30.7794% 鈉-CMC XL (崩解劑) 9.6386% Aerosil 200 (助流劑) 0.4819% 硬脂酸鎂 (潤滑劑) 0.9639% 膜包衣Opadry (HPMC) 3.6145%製造製程 將來自實例1之固體分散醫藥中間體(19.7063 kg)、甘露醇DC (25.5469 kg)、纖維素MK GR (25.5469 kg)、鈉-CMC XL (8.000 kg)及Aerosil 200 (0.4 kg)摻和在一起並篩分。添加硬脂酸鎂(0.8 kg)並然後將經摻和之混合物製錠。將所得錠劑視情況用非功能性膜包衣進行膜包衣。實例 9 ：包含化合物 A.HCl 之臨床服務調配物 1 ( 「 CSF1 」 ) 錠劑 ( 標準調配物 ) 將1 kg化合物A (游離鹼)在環境溫度下置於4.711 kg異丙醇中。然後在60℃下加熱混合物。然後添加鹽酸溶液(0.197 kg HCl 10N + 1.4 kg水)。將混合物攪拌90分鐘，然後冷卻至10℃。當結晶完成時，過濾懸浮液，用水洗滌並在50℃下乾燥。然後將產物微粉化，然後與賦形劑如下摻和： 將所微粉化之產物與十二烷基硫酸鈉混合。然後，將預混合物添加至微晶纖維素、乳糖一水合物、交聯羧甲基纖維素鈉及羥丙基纖維素中。使用濕法粒化(習用製造製程)在行星式粒化器中將混合物粒化。在行星式粒化器或在烘箱系統中乾燥後，篩分顆粒。然後添加硬脂酸鎂(潤滑劑)及二氧化矽(助流劑)用於外相：篩分並壓製經潤滑之顆粒，以獲得錠劑。最後，將錠劑用白色預混合物(Sepifilm編號37781 RBC)進行膜包衣。 組合物/具有膜包衣之錠劑(重量/錠劑之重量%)： 化合物A.HCl 15.17% 微晶纖維素 22.72% 交聯羧甲基纖維素鈉 2.90% 羥丙基纖維素 6.77% 乳糖一水合物 45.04% 十二烷基硫酸鈉 2.90% 硬脂酸鎂 0.97% 膠態無水二氧化矽 0.19%膜包衣 甘油 0.15% 羥丙基甲基纖維素 2.43% Macrogol 6000 0.16% 硬脂酸鎂 0.15% 二氧化鈦 0.47%The term "solid dispersed pharmaceutical intermediate" as used herein means an amorphous drug substance dispersed in a polymeric solid matrix carrier. It is intended that this form of intermediate is formulated into a pharmaceutical composition in the form of a pharmaceutical dosage form to promote the dissolution of the drug substance in the gastrointestinal tract and maintain the drug in a supersaturated state to be absorbed. Solid dispersion pharmaceutical intermediate systems are produced by techniques known in the industry, such as spray drying, solvent evaporation, kneading, co-precipitation, hot melt extrusion, and melt freezing. The term "solid dispersion polymer" as used herein means a polymer or mixture of polymers suitable for obtaining a stable solid dispersion of an amorphous drug substance in a reproducible and industrially feasible manner. The drug substance molecules are distributed in a solid matrix that prevents them from forming crystal lattices. According to the invention, the following solid dispersion polymers can be used: (i) Vinyl polymers, including polyvinyl esters (e.g. polyvinyl acetate phthalate) and homopolymers and copolymers based on polyvinylpyrrolidone (e.g. poly Vinylpyrrolidone (PVP, such as PVP K30 available from BASF) and copovidone (ie, vinylpyrrolidone-vinyl acetate copolymer, such as Kollidon® VA64 available from BASF) and polyvinyl hexyl Lactoamide-polyvinyl acetate-polyethylene glycol graft copolymer (eg Soluplus® available from BASF); (ii) cellulose compounds, including cellulose ethers or esters, such as methyl cellulose (MC) , Hydroxypropyl methyl cellulose (HPMC) and hydroxypropyl cellulose (HPC) compounds and more particularly HPMC E5 (e.g. Methocel® E5 available from Dow), HPMC E15 (which is available from Ashland), HPMC- 3CPS (which is available from Dow), Klucel® EF (which is HPC and available from Ashland), HPMC acetate succinate (HPMC-AS) (e.g. Aqoat® available from Shi-Etsu) or HPMC phthalate (HPMC-P, which is available from ShinEtsu); (iii) Polymethacrylate or methacrylic acid copolymer, which corresponds to The fully polymerized methacrylic acid and acrylate or methacrylate of the copolymer (e.g. Eudragit® can be obtained from the Evonik). The solid dispersion pharmaceutical intermediate of the present invention can be formulated with one or more other pharmaceutically acceptable inactive ingredients (commonly referred to as pharmaceutical excipients, such as fillers, disintegrants, lubricants, glidants) To form a pharmaceutical composition for oral administration. "X90 particle size" means the particle size corresponding to 90% of the cumulative distribution under the sieve. For example, laser light diffraction can be used to perform the test. Fillers are well known to skilled formulators. Optional fillers include lactose, mannitol (eg, mannitol DC suitable for direct tableting), sorbitol, glucose, dextrose, calcium carbonate, calcium phosphate, hydroxypropyl methylcellulose (HPMC) and micro Crystalline cellulose (cellulose MK GR). Disintegrants are well known to skilled formulators. Common disintegrants include croscarmellose sodium (Na-CMC XL, also known as "natrium-CMC XL" or "sodium-CMC-XL" or "croscarmellose" Croscarmellose sodium "), starch or modified starch (eg sodium starch glycolate, corn starch) and crospovidone (ie cross-linked polyvinylpyrrolidone, such as available from Ashland Plasdone XL10). Lubricants are well known to skilled formulators. Lubricants generally available include stearic acid, magnesium stearate, stearyl fumarate, talc, glyceryl behenate, and castor oil. Glidants are well known to skilled formulators. Commonly selected glidants include silica (for example, Aerosil® 200 available from Evonik), magnesium stearate, and talc. The term "pharmaceutical composition for oral administration" means, for example, a lozenge or capsule, especially a lozenge. This lozenge can be film coated as appropriate. "A.HCl compound" or "compound A.HCl salt" means N - (4- hydroxyphenyl) -3- {6 - [(( 3 S) -3- (4- morpholin-ylmethyl) - 3,4-dihydro-2 (1 H ) -isoquinolinyl) carbonyl] -1,3-benzodioxol-5-yl} -N -phenyl-5,6,7, 8-Tetrahydro-1-indazinecarboxamide hydrochloride. The term "comprising" as used herein means "including" and unless the context indicates otherwise, such as when the components add up to 100% together, it is not intended to exclude the presence of any additional components. The term "solvent" means a solvent capable of dissolving Compound A and the selected polymer. Preferably, it will be: (i) polar protic solvents, such as alcohol and more particularly methanol and ethanol; (ii) non-polar protic solvents, such as acetone and methylene chloride; (iii) a mixture of these solvents; or ( iv) A mixture of their solvents and water. "Cancer" means a type of disease in which groups of cells exhibit uncontrolled growth. Cancer types include hematological cancer (lymphoma and leukemia) and solid tumors, including carcinoma, sarcoma or blastoma. "Cancer" includes bladder cancer, brain cancer, breast cancer and uterine cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer and liver cancer, lymphoblastic leukemia, non-Hodgkin lymphomas, melanin Tumor, hematological malignancy, myeloma, ovarian cancer, non-small cell lung cancer, prostate cancer and small cell lung cancer. "Free molecule" and "free base" are used interchangeably herein and refer to Compound A when not in salt form. Embodiments of the invention Several embodiments of the invention are explained below. . E1 solid dispersion pharmaceutical intermediates, which comprises the free form of the molecule, or a pharmaceutically pharmaceutically acceptable salt forms of N - (4- hydroxyphenyl) -3- {6 - [(( 3 S) -3- (4- do (Polinylmethyl) -3,4-dihydro-2 (1 H ) -isoquinolinyl) carbonyl] -1,3-benzodioxol-5-yl} -N -phenyl- 5,6,7,8-tetrahydro-1-indazinecarboxamide (compound A), and one or more solid dispersion polymers. E2. The solid dispersion pharmaceutical intermediate as in Example 1, which contains 10% to 60% by weight of Compound A free molecules or pharmaceutically acceptable salts. E3. The solid dispersed pharmaceutical intermediate as in Example 2, which contains 20% to 50% by weight of Compound A free molecule or pharmaceutically acceptable salt. E4. The solid dispersed pharmaceutical intermediate as in Example 3, which contains 35 to 45% by weight, preferably 40% by weight of Compound A free molecule or a pharmaceutically acceptable salt. E5. The solid dispersed pharmaceutical intermediate as in any one of embodiments 1, 2, 3, or 4, which comprises Compound A. HCl salt. E6. The solid dispersion pharmaceutical intermediate as in any one of embodiments 1 to 5, which comprises a solid dispersion polymer selected from the group consisting of: polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol Branched copolymers (eg Soluplus®), polyvinylpyrrolidone K30 (PVP K30), hydroxypropyl methylcellulose E5 (HPMC E5), hydroxypropyl cellulose (eg Klucel® EF), hydroxypropyl Methyl cellulose acetate succinate (for example, Aqoat®) and copovidone (for example, Kollidon® VA64), preferably the solid dispersion polymer is selected from polyvinylpyrrolidone K30 (PVP K30), hypromellone Methyl cellulose E5 (HPMC E5), hydroxypropyl methyl cellulose acetate succinate (Aqoat®) and copovidone (eg Kollidon® VA64), more preferably the solid dispersion polymer is selected from polyvinyl Pyrrolidone K30 (PVP K30), hydroxypropylmethyl cellulose acetate succinate (Aqoat®) and copovidone (Kollidon® VA64). E7. The solid dispersion pharmaceutical intermediate as in Example 6, which comprises a solid dispersion polymer which is copovidone (Kollidon® VA64) or hydroxypropyl methylcellulose acetate succinate (Aqoat®). E8. The solid dispersion pharmaceutical intermediate as in Example 7 which contains a solid dispersion polymer which is copovidone (Kollidon® VA64). E9. The solid dispersion pharmaceutical intermediate as in Example 8, which contains about 60% by weight of copovidone (Kollidon® VA64). E10. The solid dispersed pharmaceutical intermediate as in any one of Examples 1 to 9, which is manufactured by a spray drying process. E11. A pharmaceutical composition for oral administration, comprising a solid of any one of Examples 1 to 10 in an amount of 10% to 80% by weight of the total composition, especially 10% to 50% by weight Disperse pharmaceutical intermediates. E12. The pharmaceutical composition for oral administration as in Example 11, which comprises a solid dispersed pharmaceutical intermediate in an amount of 20% to 30% by weight, especially 22% to 26% by weight of the total composition. E13. The pharmaceutical composition for oral administration as in Example 11 or 12, which contains at least one filler selected from the group consisting of lactose, mannitol, calcium carbonate, calcium phosphate, and hydroxypropyl methylcellulose (E HPMC) and microcrystalline cellulose (cellulose MK GR). E14. The pharmaceutical composition for oral administration as in Example 11, 12 or 13, which contains one or more fillers, the total amount of fillers is 10% to 90% by weight of the total composition, especially 30 Weight percent to 90 weight percent, more specifically 55 weight percent to 67 weight percent. E15. The pharmaceutical composition for oral administration as in any one of Examples 11 to 14, which includes both mannitol and cellulose MK GR. E16. The pharmaceutical composition for oral administration as in any one of embodiments 11 to 15, which comprises 5 to 50% by weight of the total composition, especially 20 to 45% by weight, more specifically Mannitol in an amount of 30% to 35% by weight. E17. The pharmaceutical composition for oral administration as in any one of embodiments 11 to 16, which comprises 5 to 50% by weight of the total composition, especially 20 to 40% by weight, more specifically Said cellulose MK GR in an amount of 30% to 35% by weight. E18. The pharmaceutical composition for oral administration as in any one of embodiments 11 to 17, which includes both mannitol and cellulose MK GR, where mannitol is 20% by weight to 45% of the total composition The amount by weight is present, and cellulose MK GR is present in an amount of 20% to 40% by weight. E19. The pharmaceutical composition for oral administration as in any one of embodiments 11 to 18, which includes: a. Mannitol in an amount of 30% by weight to 35% by weight, and b. 30% by weight to 35 Cellulose MK GR in an amount of% by weight. E20. The pharmaceutical composition for oral administration as in any one of embodiments 11 to 19, wherein the composition comprises at least one disintegrant selected from croscarmellose sodium ( Na-CMC XL), sodium starch glycolate, corn starch and crospovidone (Plasdone XL10). E21. The pharmaceutical composition for oral administration as in any one of Examples 11 to 20, which contains a disintegrant in an amount of 3% to 20% by weight. E22. The pharmaceutical composition for oral administration as in Example 21, which contains a disintegrant in an amount of 7% to 13% by weight, especially 10% by weight. E23. The pharmaceutical composition for oral administration as in any one of embodiments 20 to 22, wherein the disintegrant is croscarmellose sodium (sodium-CMC XL). E24. The pharmaceutical composition for oral administration as in any one of embodiments 11 to 23, which comprises at least one glidant. E25. The pharmaceutical composition for oral administration as in Example 24, wherein the total amount of glidant is present in an amount of 0.1% to 5% by weight. E26. The pharmaceutical composition for oral administration as in Example 25, which contains a glidant in an amount of 0.2% to 0.8% by weight. E27. The pharmaceutical composition for oral administration as in any one of embodiments 24 to 26, which contains a glidant, which is silica (eg Aerosil 200). E28. The pharmaceutical composition for oral administration as in any one of embodiments 11 to 27, wherein the composition contains a lubricant. E29. The pharmaceutical composition for oral administration as in Example 28, wherein the composition contains a lubricant selected from the group consisting of stearic acid, magnesium stearate, stearyl fumarate, and talc , Glyceryl behenate and castor oil. E30. The pharmaceutical composition for oral administration as in Example 29, which contains a lubricant, which is magnesium stearate. E31. The pharmaceutical composition for oral administration as in any one of embodiments 28 to 30, which contains at least one lubricant in an amount of 0.1% to 5% by weight, especially 0.5% to 1.5% by weight. E32. The pharmaceutical composition for oral administration as in any one of Examples 11 to 31, which is in the form of a lozenge, optionally film coated. E33. The pharmaceutical composition for oral administration as in any one of embodiments 11 to 32, which contains 5 mg to 150 mg, especially 25 mg, 50 mg, 75 mg, and 100 mg of Compound A free molecule. E34. A pharmaceutical composition for oral administration, comprising: ● a solid dispersed pharmaceutical intermediate as in any one of Examples 1 to 10, and ● a filler selected from mannitol DC and lactose. E35. The pharmaceutical composition as in Example 34, which comprises the following lozenges: ● The solid dispersed pharmaceutical intermediate as in any one of Examples 1 to 10, and ● A filler selected from mannitol DC and lactose. E36. The pharmaceutical composition as in Example 35, which comprises the following lozenges: ● The solid dispersion pharmaceutical intermediate as in any one of Examples 1 to 10, and ● Mannitol DC. E37. The pharmaceutical composition as in Example 34, which comprises the following lozenges: ● The solid dispersion pharmaceutical intermediate as in any one of Examples 1 to 10, ● Mannitol DC and ● Croscarmellose Sodium (sodium CMC XL). E38. A lozenge for oral administration as in any of embodiments 35 to 37, which contains 5 mg to 150 mg, especially 25 mg, 50 mg, 75 mg, and 100 mg of compound A free molecules. E39. A method of modulating Bcl-2 receptor activity in an individual, wherein the method comprises administering to the individual a therapeutically effective amount of the composition of any one of embodiments 11 to 38. E40. A method of treating a condition or disease selected from cancer, immune system diseases, and autoimmune diseases, which comprises administering to the individual a therapeutically effective amount of the composition of any one of embodiments 11 to 38. E41. The method of embodiment 40, wherein the cancer is selected from bladder cancer, brain cancer, breast cancer and uterine cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer and liver cancer, lymphoblastic leukemia, non-Hodgkin's Lymphoma, melanoma, hematological malignancies, myeloma, ovarian cancer, non-small cell lung cancer, prostate cancer, and small cell lung cancer. E42. The pharmaceutical composition according to any one of embodiments 11 to 38, which is used as a medicament. E43. The pharmaceutical composition according to any one of embodiments 11 to 38, which is used for the treatment of a condition or disease selected from cancer, immune system diseases and autoimmune diseases. E44. The pharmaceutical composition according to any one of embodiments 11 to 38, which is used to treat cancer, wherein the cancer is selected from bladder cancer, brain cancer, breast cancer and uterine cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer and Liver cancer, lymphoblastic leukemia, non-Hodgkin's lymphoma, melanoma, hematological malignancies, myeloma, ovarian cancer, non-small cell lung cancer, prostate cancer, and small cell lung cancer. E45. A combination comprising: ● the pharmaceutical composition as in any one of embodiments 11 to 38, and ● one or more therapeutically active agents used simultaneously, sequentially or separately. E46. A method for preparing a solid dispersion pharmaceutical intermediate as in any one of Examples 1 to 10, which includes the following steps: (i) Compound A or a pharmaceutically acceptable salt thereof and a solid dispersion polymer in one or Mix in multiple solvents, (ii) spray dry the resulting solution, and (iii) evaporate the solvent. E47. A method for preparing a solid dispersion pharmaceutical intermediate as in any one of Examples 1 to 10, which consists of the following: (i) Compound A or a pharmaceutically acceptable salt thereof is combined with a solid dispersion polymer Or mixed in multiple solvents, (ii) spray drying the resulting solution, and (iii) evaporating the solvent. E48. The method of embodiment 46 or 47, wherein the solvent is a mixture of methanol / acetone or a mixture of methanol / dichloromethane. E49. The solid dispersed pharmaceutical intermediate as in any one of embodiments 1 to 10, wherein the solid dispersed pharmaceutical intermediate has an x90 particle size of 20 to 35 microns. Another embodiment provides a pharmaceutical composition for oral administration as in any of the embodiments herein, wherein the composition optionally includes a surfactant selected from the group consisting of: poloxamer (poloxamer, such as Kolliphor P188) (Which is available from BASF)), sodium lauryl sulfate, polysorbate 80 (Tween 80), Tween 20, polyoxyethylene 35 (Polyoxyl 35) hydrogenated castor oil (e.g. Kolliphor® ELP (which is available from BASF) obtain)). Another embodiment provides a pharmaceutical composition for oral administration as in any of the embodiments herein, wherein the composition optionally includes a binder selected from the group consisting of povidone (eg PVP K30), malt Dextrin (eg Lycatab® DSH from Roquette), HPMC (eg Pharmacoat® 606 from Shin-Etsu) and HPC (eg HPC-L). Another embodiment provides a pharmaceutical composition for oral administration as in any of the embodiments herein, wherein the composition optionally includes a film coating. Lozenge film coating is an alternative embodiment of the invention. It can be selected to prevent moisture uptake and / or abrasion and provide a physical barrier between the active drug substance and the external environment. Skilled formulators can select appropriate film coatings according to those familiar with the industry. For example, coatings based on HPMC or PVA can be used, such as Opadry ® (based on HPMC), Opadry II ® (based on PVA), and OpadryAMB II ® (based on PVA). The solid dispersion pharmaceutical intermediates described herein can be used to provide compositions that can increase the bioavailability of Compound A. In addition, it has been surprisingly found that certain embodiments of the present invention provide additional advantages. For example, when the following polymers are used in solid dispersion pharmaceutical intermediates: polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus®), polyvinylpyrrolidone (PVP K30), hydroxypropyl methylcellulose (HPMC E5), HPC (Klucel® EF), HPMC acetate succinate (Aqoat®) or vinylpyrrolidone-vinyl acetate copolymer (Kollidon® VA64) , A low rate of degradation was observed without the crystallization of compound A, and specifically for polyvinylpyrrolidone (PVP K30), hydroxypropyl methylcellulose (HPMC E5), HPC (Klucel® EF), HPMC Acetate succinate (Aqoat®) or vinylpyrrolidone-vinyl acetate copolymer (Kollidon® VA64). In addition, polymers polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus®), polyvinylpyrrolidone (PVP K30), hydroxypropyl methylcellulose (HPMC E5), HPMC acetate succinate (Aqoat®) and vinylpyrrolidone-vinyl acetate copolymer (Kollidon® VA64) can be highly exposed in rats, especially polyvinylpyrrolidone (PVP K30), Hydroxypropyl methylcellulose (HPMC E5), HPMC acetate succinate (Aqoat®) and vinylpyrrolidone-vinyl acetate copolymer (Kollidon® VA64). For the pharmaceutical compositions described herein containing solid dispersed pharmaceutical intermediates, certain components or amounts of components have been found to provide unexpected benefits. As explained in the examples herein, when mannitol and cellulose filler are used in a ratio of about 1: 1, another unexpected advantage is identified. These ratios improve the fluidity of the composition, thereby reducing or avoiding gelation. Gelation can complicate manufacturing and can also delay the release of Compound A. EXAMPLES Example 1 : A solid dispersed pharmaceutical intermediate containing Compound A. HCl Composition (% by weight): Compound A. HCl salt 40% Kollidon® VA64 60% Methanol removes acetone during the manufacturing process Removes the manufacturing process feed during the manufacturing process Solution preparation: Methanol (19.584 kg) and acetone (19.584 kg) were filled into a container and agitated at room temperature. Compound A. HCl (1 kg) was added and the mixture was stirred until the solution became clear. Then add Kollidon ® VA64 (1.5 kg) and stir the mixture until the solution becomes almost clear. Spray drying: Depending on the batch size, different equipment with different spray drying parameters can be used to spray dry the feed solution. Typical process parameters are described below: Device: Niro QSD3.6 Spray drying: inlet temperature 90 ℃ -180 ℃, outlet temperature 60 ℃ -70 ℃ (target 65 ℃), feed rate 10-30 (kg / h), The process gas flow rate is 360 Kg / hr. The device and spray drying parameters can be modified as needed. Secondary vacuum drying: Typical parameters of secondary vacuum drying: temperature 60 ℃ -70 ℃, drying pressure <10 [mbar abs], optional nitrogen purge. Drying conditions can vary with batch size. For example, for larger batches, the solid dispersion particles can be partially dried using a nitrogen stream at 45 ° C to 70 ° C under vacuum until the residual solvent and water content specifications are met. The x90 particle size of the solid dispersion intermediate obtained from the process described above is usually 20 microns to 35 microns. Example 2 : Mannitol-containing clinical service formulation 2 ( " CSF2A " ) lozenges A manufacturing process similar to that described in Example 8 was used. Example 3 : Lozenges containing lactose A manufacturing process similar to that described in Example 8 was used. Example 4 : PK in dogs pretreated with pentagastrin after oral administration of Compound A. HCl salt The target of this study was male Beagle dogs pretreated with pentagastrin After oral administration of 100 mg of Compound A of the formulations of Examples 2 and 3 herein, the concentration-time course was measured and the pharmacokinetic parameters of Compound A. HCl salt were evaluated. The tablets of both Examples 2 and 3 were coated with Opadry (HPMC) for this study. Animals Male beagle dogs (n = 4 / treatment / crossover design) Fast the dogs for> 15 hours (overnight) before dosing. On the day of dosing, provide a daily portion of 250 g-350 g of food (dog diet: Art. Nr. 3353 Provimi Kliba SA, 4303 Kaiseraugst, Switzerland) shortly after 4 hours of dosing. All animals have free access to tap water. Preparation of pentagastrin and administration to dogs To reduce the pH in the stomach and simulate human acidic conditions, pentagastrin (6 µg / kg) was administered intramuscularly 45 minutes before administration of compound A.HCl . To prepare a solution, pentagastrin was newly dissolved in PEG400, and then water was added under continuous stirring to achieve a 10% (v / v) PEG400 solution (PEG400: water, 1: 9, v: v), where The final concentration of pentagastrin is 80 µg / mL. The volume of intramuscular administration using a 23 G needle was 0.075 mL / kg. Formulations and dosing The interval between each dosing period is at least 3 days. The formulation was administered by deep-throat application of a total of 100 mg of Compound A per dog 4 tablets, followed by rinsing with 20 mL of drinking water. Biological sample collection and disposal Sampling summary At the time points presented in the table below, blood was collected from the cephalic vein in an Eppendorf tube coated with EDTA (approximately 1 mL / time point). Immediately after collection, place the blood sample on ice. After collection, the blood was centrifuged within 15 min (3000 g, 10 min, 4 ° C). Plasma was prepared and stored at -80 ° C until the sample was analyzed. Timetable for sample collection for biological analysis EDTA: Quantification of Ethylenediaminetetraacetic acid Compound A The plasma concentration of Compound A was measured. Using 20 µL of plasma, the LLOQ (lower limit of quantification) of Compound A was 0.200 ng / mL. Data evaluation of pharmacokinetic parameters The concentration and pharmacokinetic parameters (except Tmax and Tlast) are rounded to 3 significant digits. All non-compartmental methods (WinNonlin, version 6.3, Pharsight Corporation Mountain View, CA, USA) were used to calculate all pharmacokinetic parameters with the help of phoenix WinNonlin® software. Pharmacokinetic results All dogs were treated in a cross-over design in which a nominal 100 mg of Compound A was administered orally to each animal. All dogs were pretreated with pentagastrin 45 minutes before compound A administration. The plasma concentration-time course of Compound A is shown in Figure 1. After administration of 100 mg / dog Compound A in the composition of Example 3, plasma exposure totaled an average Cmax / dose of 27.1 ± 9.77 ng / mL / (mg / kg) and 86.1 ± 17.5 h · ng / mL / ( mg / kg) AUC last / dose. After administration of 100 mg / canine Compound A in the composition of Example 2 (CSF2A), plasma exposure totaled an average Cmax / dose of 40.7 ± 24.3 ng / mL / (mg / kg) and 134 ± 55.3 h · ng / The average AUC last time / dose in mL / (mg / kg). At 1 h after dosing, the median Tmax was reached for all formulations. After administration of Compound A in dogs, the dose-normalized Cmax (Cmax / dose) and the dose-normalized AUC / last (AUC last / dose) animal variability estimated by the coefficient of variation (CV) were 28.7% to In the range of 59.7% and 20.3% to 41.3%, this shows the highest variability when the composition of Example 2 (CSF2A) was administered. High exposure was achieved by Examples 2 and 3. However, the highest exposure was achieved by Example 2 with a compromise of higher variability in dogs. Example 5 : Alternative solid dispersion pharmaceutical intermediates containing compound A.HCl . Polymers selected from the following groups have been used to prepare different solid dispersion pharmaceutical intermediates: Soluplus®, polyvinylpyrrolidone K30 (PVP K30), Hydroxypropyl methylcellulose E5 (HPMC E5), Klucel® EF, Aqoat® (HPMC AS-LF) and Kollidon® VA64. Composition (wt%): Compound A. HCl salt 30% Polymer 70% Methanol was removed during the manufacturing process Dichloromethane was removed during the manufacturing process Manufacturing process was weighed Compound A. HCl (3 g) and selected in a beaker Polymer (7 g). Methanol (100 mL) and dichloromethane (100 mL) were added and magnetically stirred at room temperature until the solution became clear, which means that compound A.HCl and the selected polymer were completely dissolved. The resulting solution was spray dried at an outlet temperature of 50 ° C and a flow rate of 8 mL / min. In parallel, an amorphous compound A. HCl was also obtained using a similar spray drying process without adding any polymer as described below: Compound A. HCl (10 g) was weighed in a beaker. Methanol (150 mL) and dichloromethane (150 mL) were added and magnetically stirred at room temperature until the solution became clear, which means that compound A.HCl was completely dissolved. The resulting solution was spray dried at an outlet temperature of 50 ° C and a flow rate of 8 mL / min. Example 6: Compound A.HCl comprising a solid dispersion of pharmaceutical intermediates, physical and chemical stability of the solid obtained in Example 5 was dispersed and spray-dried pharmaceutical intermediates of compound A. HCl (i.e., without polymer) is stored in Denatured temperature and relative humidity. After storage at 40 ° C / 75% RH (relative humidity) and at 50 ° C for 1 month, the ratio of degradation products was measured using HPLC / UV. It also monitors the physical stability of amorphous solid pharmaceutical intermediates by X-ray diffraction. Results For all polymers tested, after storing at 40 ° C / 75% RH for 1 month and at 50 ° C for 1 month, a low rate of degradation products was observed. In addition, no crystallization was observed under the previous conditions. The solid dispersed pharmaceutical intermediate obtained in Example 5 allows the compound A. HCl in an amorphous form to be stable under denatured storage conditions (ie, 40 ° C / 75% RH and 50 ° C) for 1 month. Example 7 : After oral administration of the compound A.HCl suspension prepared from the solid dispersion pharmaceutical intermediate obtained in Example 6 , the PK in rats The goal of this study was to determine the oral administration of 100 mg / kg of compound After A, the pharmacokinetic parameters were measured in rats. A suspension was prepared by dissolving the solid dispersion pharmaceutical intermediate of Example 5 in 1% HEC (hydroxyethyl cellulose) in purified water. Animals and Compound A. HCl dose value Compound A. HCl was orally administered to male Wistar rats at a dose of 100 mg / kg (expressed as free base) (n = 3 / formulation, animals were not fasted). The rats were administrated by gastric tube infusion at a volume of 10 mL / kg. Samples At 30 min, 1 h, 2 h, 4 h, 8 h, and 24 h after administration, blood samples (approximately 0.1 mL) were collected from the tail vein into heparin sodium tubes at room temperature. Immediately after each extraction, the blood was centrifuged to obtain plasma, and stored frozen in airtight plastic tubes at -70 ° C or lower. Analysis The samples were thawed at room temperature, vortexed and centrifuged (5 min, 4 ° C, 3,000 rpm). Add an aliquot (20 μL) of the sample to the OSTRO plate containing 20 μL of the standard solution in 30.0 ng / mL Y 2202 in acetonitrile, then add 150 μL of acetonitrile. The plate was mixed at 1,000 rpm for 1 min at room temperature and the compound was eluted in a 96-well plate. The samples were analyzed by liquid chromatography using ESI + Tandem Mass Spectrometry (UPLC / MS-MS), where the limit of quantification = 0.1 ng / mL. Pharmacokinetic results The results show that the exposure in rats is high and dependent on the formulation. The best polymers for AUC 24 obtained were Aqoat® and Kollidon® VA64, followed by PVP K30 and HPMC E5, and again Soluplus. T max was observed in the range of 2h-4h for all formulations. Example 8 : Clinical Service Formulation 2 ( “ CSF2B ” ) lozenge composition / tablet- free coated lozenge (weight / weight of lozenge): solid dispersed pharmaceutical intermediate from Example 1 24.6328% mannitol DC ( Filler) 31.9336% cellulose MK GR (filler) 31.9336% sodium-CMC XL (disintegrant) 10.0000% Aerosil 200 (glidant) 0.5000% magnesium stearate (lubricant) 1.0000% composition / with film Coated lozenges (wt / wt% of lozenges): Solid dispersed pharmaceutical intermediate from Example 1 23.7425% mannitol DC (filler) 30.7794% cellulose MK GR (filler) 30.7794% sodium-CMC XL ( (Disintegrant) 9.6386% Aerosil 200 (Glidant) 0.4819% Magnesium stearate (lubricant) 0.9639% Film-coated Opadry (HPMC) 3.6145% Manufacturing process The solid dispersion pharmaceutical intermediate from Example 1 (19.7063 kg) , Mannitol DC (25.5469 kg), cellulose MK GR (25.5469 kg), sodium-CMC XL (8.000 kg) and Aerosil 200 (0.4 kg) are blended together and sieved. Magnesium stearate (0.8 kg) was added and the blended mixture was then made into tablets. The resulting lozenges are film coated with non-functional film coating as appropriate. Example 9 : Clinical service formulation 1 ( " CSF1 " ) lozenge ( standard formulation ) containing compound A.HCl 1 kg of compound A (free base) was placed in 4.711 kg isopropanol at ambient temperature. The mixture was then heated at 60 ° C. Then hydrochloric acid solution (0.197 kg HCl 10N + 1.4 kg water) was added. The mixture was stirred for 90 minutes and then cooled to 10 ° C. When crystallization is complete, the suspension is filtered, washed with water and dried at 50 ° C. The product was then micronized and then blended with excipients as follows: The micronized product was mixed with sodium lauryl sulfate. Then, the premix was added to microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and hydroxypropyl cellulose. The mixture is granulated in a planetary granulator using wet granulation (conventional manufacturing process). After drying in a planetary granulator or in an oven system, the particles are sieved. Then add magnesium stearate (lubricant) and silicon dioxide (glidant) for the external phase: sieve and compress the lubricated particles to obtain a lozenge. Finally, the lozenges were film coated with a white premix (Sepifilm number 37781 RBC). Composition / lozenges with film coating (weight / wt% of lozenges): Compound A. HCl 15.17% microcrystalline cellulose 22.72% croscarmellose sodium 2.90% hydroxypropyl cellulose 6.77% lactose Monohydrate 45.04% Sodium dodecyl sulfate 2.90% Magnesium stearate 0.97% Colloidal anhydrous silica 0.19% Film-coated glycerol 0.15% Hydroxypropyl methylcellulose 2.43% Macrogol 6000 0.16% Magnesium stearate 0.15% Titanium dioxide 0.47%

圖1：單一經口投用實例2及3調配物中100 mg化合物A後，血漿中之化合物A濃度及PK參數。 圖2：單一經口投用實例2及3調配物中100 mg化合物A後，犬中之化合物A血漿濃度-時程。Figure 1: Plasma Compound A concentration and PK parameters after single oral administration of 100 mg of Compound A in the formulations of Examples 2 and 3. Figure 2: Plasma concentration-time course of compound A in dogs after single oral administration of 100 mg of compound A in the formulations of Examples 2 and 3.

Claims (32)

一種固體分散醫藥中間體，其包含N -(4-羥基苯基)-3-{6-[((3S )-3-(4-嗎啉基甲基)-3,4-二氫-2(1H )-異喹啉基)羰基]-1,3-苯并二氧雜環戊烯(benzodioxol)-5-基}-N -苯基-5,6,7,8-四氫-1-吲嗪甲醯胺(化合物A)呈游離分子或醫藥上可接受之鹽，及一或多種固體分散聚合物。A solid dispersion pharmaceutical intermediates, comprising N - (4- hydroxyphenyl) -3- {6 - [(( 3 S) -3- (4- morpholinyl) -3,4-dihydro - 2 (1 H ) -isoquinolinyl) carbonyl] -1,3-benzodioxol-5-yl} -N -phenyl-5,6,7,8-tetrahydro -1-Indazine formamide (compound A) is a free molecule or a pharmaceutically acceptable salt, and one or more solid dispersion polymers. 如請求項2之固體分散醫藥中間體，其包含35重量%至45重量%、較佳40重量%之化合物A游離分子或醫藥上可接受之鹽。The solid dispersion pharmaceutical intermediate as claimed in claim 2, which contains 35% to 45% by weight, preferably 40% by weight of Compound A free molecule or a pharmaceutically acceptable salt. 如請求項1或2之固體分散醫藥中間體，其包含化合物A.HCl鹽。The solid dispersion pharmaceutical intermediate as claimed in claim 1 or 2, which comprises Compound A. HCl salt. 如請求項1至3中任一項之固體分散醫藥中間體，其包含選自以下之固體分散聚合物：聚乙烯基己內醯胺-聚乙酸乙烯酯-聚乙二醇接枝共聚物(Soluplus®)、聚乙烯基吡咯啶酮K30 (PVP K30)、羥丙基甲基纖維素E5 (HPMC E5)、羥丙基纖維素(Klucel® EF)、HPMC乙酸琥珀酸酯(Aqoat®，HPMC AS-LF)及乙烯基吡咯啶酮-乙酸乙烯酯共聚物(Kollidon® VA64)。The solid dispersion pharmaceutical intermediate according to any one of claims 1 to 3, which comprises a solid dispersion polymer selected from the group consisting of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer ( Soluplus®), polyvinylpyrrolidone K30 (PVP K30), hydroxypropylmethyl cellulose E5 (HPMC E5), hydroxypropyl cellulose (Klucel® EF), HPMC acetate succinate (Aqoat®, HPMC AS-LF) and vinylpyrrolidone-vinyl acetate copolymer (Kollidon® VA64). 如請求項4之固體分散醫藥中間體，其包含約60重量%之乙烯基吡咯啶酮-乙酸乙烯酯共聚物(Kollidon® VA64)。The solid dispersion pharmaceutical intermediate as claimed in claim 4, which contains about 60% by weight of vinylpyrrolidone-vinyl acetate copolymer (Kollidon® VA64). 一種用於經口投與之醫藥組合物，其包含總組合物之10重量%至80重量%、特別是10重量%至50重量%之量之如請求項1至5中任一項之固體分散醫藥中間體。A pharmaceutical composition for oral administration, comprising the solid of any one of claims 1 to 5 in an amount of 10% to 80% by weight of the total composition, particularly 10% to 50% by weight Disperse pharmaceutical intermediates. 如請求項6之用於經口投與之醫藥組合物，其包含至少一種選自以下之填充劑：乳糖、甘露醇、碳酸鈣、磷酸鈣、交聚維酮、羥丙基甲基纖維素(HPMC)及微晶纖維素(纖維素MK GR)。The pharmaceutical composition for oral administration according to claim 6, which contains at least one filler selected from the group consisting of lactose, mannitol, calcium carbonate, calcium phosphate, crospovidone, and hydroxypropyl methylcellulose (HPMC) and microcrystalline cellulose (cellulose MK GR). 如請求項6或7之用於經口投與之醫藥組合物，其包含一或多種填充劑，填充劑之總量係總組合物之10重量%至90重量%、特別是30重量%至90重量%，更特別是55重量%至67重量%。The pharmaceutical composition for oral administration as claimed in claim 6 or 7 contains one or more fillers, the total amount of fillers is 10% to 90% by weight of the total composition, especially 30% to 90% by weight, more particularly 55% to 67% by weight. 如請求項6至8中任一項之用於經口投與之醫藥組合物，其包含甘露醇及纖維素MK GR二者。The pharmaceutical composition for oral administration according to any one of claims 6 to 8, which contains both mannitol and cellulose MK GR. 如請求項6至9中任一項之用於經口投與之醫藥組合物，其包含甘露醇及纖維素MK GR二者，其中甘露醇係以總組合物之20重量%至45重量%之量存在，且纖維素MK GR係以20重量%至40%重量之量存在。The pharmaceutical composition for oral administration according to any one of claims 6 to 9, which comprises both mannitol and cellulose MK GR, wherein mannitol is 20% to 45% by weight of the total composition And the cellulose MK GR is present in an amount of 20% to 40% by weight. 如請求項6至10中任一項之用於經口投與之醫藥組合物，其中該組合物包含至少一種選自以下之崩解劑：交聯羧甲基纖維素鈉(鈉-CMC XL)、羥乙酸澱粉鈉、玉米澱粉及交聚維酮(Plasdone XL10)。The pharmaceutical composition for oral administration according to any one of claims 6 to 10, wherein the composition contains at least one disintegrant selected from the group consisting of croscarmellose sodium (sodium-CMC XL ), Sodium starch glycolate, corn starch and crospovidone (Plasdone XL10). 如請求項6至11中任一項之用於經口投與之醫藥組合物，其包含3重量%至20重量%之量之崩解劑。The pharmaceutical composition for oral administration according to any one of claims 6 to 11, which contains a disintegrant in an amount of 3% to 20% by weight. 如請求項11或12之用於經口投與之醫藥組合物，其中該崩解劑係交聯羧甲基纖維素鈉(鈉-CMC XL)。The pharmaceutical composition for oral administration as claimed in claim 11 or 12, wherein the disintegrant is croscarmellose sodium (sodium-CMC XL). 如請求項6至13中任一項之用於經口投與之醫藥組合物，其包含至少一種助流劑。The pharmaceutical composition for oral administration according to any one of claims 6 to 13, which contains at least one glidant. 如請求項14之用於經口投與之醫藥組合物，其包含0.2重量%至0.8重量%之量之助流劑。The pharmaceutical composition for oral administration as claimed in claim 14 contains a glidant in an amount of 0.2% to 0.8% by weight. 如請求項14或15之用於經口投與之醫藥組合物，其包含一種助流劑，其係二氧化矽(Aerosil 200)。The pharmaceutical composition for oral administration as claimed in claim 14 or 15, which contains a glidant, which is silica (Aerosil 200). 如請求項6至16中任一項之用於經口投與之醫藥組合物，其中該組合物包含選自以下之潤滑劑：硬脂酸、硬脂酸鎂、硬脂醯富馬酸鹽、滑石、山崳酸(behenate)甘油酯及蓖麻油。The pharmaceutical composition for oral administration according to any one of claims 6 to 16, wherein the composition contains a lubricant selected from the group consisting of stearic acid, magnesium stearate, and stearyl fumarate , Talc, behenate glyceride and castor oil. 如請求項6至17中任一項之用於經口投與之醫藥組合物，其呈錠劑形式，視情況經膜包衣。The pharmaceutical composition for oral administration as claimed in any one of claims 6 to 17, which is in the form of lozenges and is optionally film coated. 如請求項6至18中任一項之用於經口投與之醫藥組合物，其包含5 mg至150 mg、特別是25 mg、50 mg、75 mg及100 mg化合物A游離分子。The pharmaceutical composition for oral administration according to any one of claims 6 to 18, which contains 5 mg to 150 mg, particularly 25 mg, 50 mg, 75 mg, and 100 mg of Compound A free molecules. 一種用於經口投與之醫藥組合物，其包含： 如請求項1至5中任一項之固體分散醫藥中間體，及 選自甘露醇DC及乳糖之填充劑。A pharmaceutical composition for oral administration, comprising: the solid dispersion pharmaceutical intermediate according to any one of claims 1 to 5, and a filler selected from mannitol DC and lactose. 如請求項20之醫藥組合物，其係包含以下之錠劑： 如請求項1至5中任一項之固體分散醫藥中間體，及 甘露醇DC。The pharmaceutical composition according to claim 20, which comprises the following lozenges: The solid dispersion pharmaceutical intermediate according to any one of claims 1 to 5, and mannitol DC. 如請求項20之醫藥組合物，其係包含以下之錠劑： 如請求項1至5中任一項之固體分散醫藥中間體， 甘露醇DC及 交聯羧甲基纖維素鈉(鈉CMC XL)。The pharmaceutical composition according to claim 20, which comprises the following lozenges: The solid dispersion pharmaceutical intermediate according to any one of claims 1 to 5, mannitol DC and croscarmellose sodium (sodium CMC XL ). 如請求項21或22之用於經口投與之醫藥組合物，其包含5 mg至150 mg、特別是25 mg、50 mg、75 mg及100 mg化合物A游離分子。The pharmaceutical composition for oral administration as claimed in claim 21 or 22, which contains 5 mg to 150 mg, especially 25 mg, 50 mg, 75 mg and 100 mg of Compound A free molecules. 一種使用如請求項6至23中任一項之醫藥組合物作為製造調節個體中Bcl-2受體活性藥劑之用途。A use of the pharmaceutical composition according to any one of claims 6 to 23 as a manufacturing agent for regulating Bcl-2 receptor activity in an individual. 一種使用如請求項6至23中任一項之醫藥組合物作為製造治療選自癌症、免疫系統疾病及自體免疫疾病之病症或疾病藥劑之用途。A use of the pharmaceutical composition according to any one of claims 6 to 23 as an agent for the treatment of a disease or disease selected from cancer, immune system diseases and autoimmune diseases. 如請求項25之用途，其中該癌症選自膀胱癌、腦癌、乳癌及子宮癌、慢性淋巴性白血病、結腸直腸癌、食道癌及肝癌、淋巴母細胞性白血病、非霍奇金氏淋巴瘤(non-Hodgkin lymphomas)、黑色素瘤、惡性血液病、骨髓瘤、卵巢癌、非小細胞肺癌、前列腺癌及小細胞肺癌。The use according to claim 25, wherein the cancer is selected from bladder cancer, brain cancer, breast cancer and uterine cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer and liver cancer, lymphoblastic leukemia, non-Hodgkin's lymphoma (non-Hodgkin lymphomas), melanoma, hematological malignancies, myeloma, ovarian cancer, non-small cell lung cancer, prostate cancer and small cell lung cancer. 如請求項6至23中任一項之醫藥組合物，其用作藥劑。The pharmaceutical composition according to any one of claims 6 to 23, which is used as a medicament. 如請求項6至23中任一項之醫藥組合物，其用於治療選自癌症、免疫系統疾病及自體免疫疾病之病症或疾病。The pharmaceutical composition according to any one of claims 6 to 23, which is used to treat a condition or disease selected from cancer, immune system diseases, and autoimmune diseases. 如請求項6至23中任一項之醫藥組合物，其用於治療癌症，其中癌症選自膀胱癌、腦癌、乳癌及子宮癌、慢性淋巴性白血病、結腸直腸癌、食道癌及肝癌、淋巴母細胞性白血病、非霍奇金氏淋巴瘤、黑色素瘤、惡性血液病、骨髓瘤、卵巢癌、非小細胞肺癌、前列腺癌及小細胞肺癌。The pharmaceutical composition according to any one of claims 6 to 23, which is used to treat cancer, wherein the cancer is selected from bladder cancer, brain cancer, breast cancer and uterine cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer and liver cancer, Lymphoblastic leukemia, non-Hodgkin's lymphoma, melanoma, hematological malignancies, myeloma, ovarian cancer, non-small cell lung cancer, prostate cancer, and small cell lung cancer. 一種組合，其包含： 如請求項6至23中任一項之醫藥組合物，及 同時、依序或分開使用之一或多種治療活性劑。A combination comprising: the pharmaceutical composition according to any one of claims 6 to 23, and the simultaneous, sequential or separate use of one or more therapeutically active agents. 一種製備如請求項1至5中任一項之固體分散醫藥中間體之方法，其包含以下步驟：(i)將化合物A或其醫藥上可接受之鹽與固體分散聚合物在一或多種溶劑中混合，(ii)將所得溶液噴霧乾燥，及(iii)蒸發出該(等)溶劑。A method for preparing a solid dispersion pharmaceutical intermediate according to any one of claims 1 to 5, comprising the following steps: (i) Compound A or a pharmaceutically acceptable salt thereof and a solid dispersion polymer in one or more solvents Medium mixing, (ii) spray drying the resulting solution, and (iii) evaporating the solvent (s). 如請求項1至5中任一項之固體分散醫藥中間體，其中該固體分散醫藥中間體之x90粒徑係20微米至35微米。The solid dispersed pharmaceutical intermediate according to any one of claims 1 to 5, wherein the x90 particle size of the solid dispersed pharmaceutical intermediate is 20 to 35 microns.
TW106122603A 2016-07-07 2017-07-05 Pharmaceutical solid dispersion of a BCL-2 inhibitor, pharmaceutical compositions thereof, and uses for the treatment of cancer TW201805003A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662359366P 2016-07-07 2016-07-07
US62/359,366 2016-07-07
EP16182455 2016-08-02
??16182455.2 2016-08-02

Publications (1)

Publication Number Publication Date
TW201805003A true TW201805003A (en) 2018-02-16

Family

ID=56681951

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106122603A TW201805003A (en) 2016-07-07 2017-07-05 Pharmaceutical solid dispersion of a BCL-2 inhibitor, pharmaceutical compositions thereof, and uses for the treatment of cancer

Country Status (3)

Country Link
TW (1) TW201805003A (en)
UY (1) UY37316A (en)
WO (1) WO2018007556A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI826570B (en) * 2018-11-06 2023-12-21 大陸商北京諾誠健華醫藥科技有限公司 Amorphous solid dispersion comprising 6-(1-acryloylpiperidin-4-yl)-2-(4-henoxyphenyl)nicotinamide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2986002B1 (en) 2012-01-24 2014-02-21 Servier Lab NOVEL INDOLIZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR3008979B1 (en) * 2013-07-23 2015-07-24 Servier Lab NOVEL PHOSPHATE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI826570B (en) * 2018-11-06 2023-12-21 大陸商北京諾誠健華醫藥科技有限公司 Amorphous solid dispersion comprising 6-(1-acryloylpiperidin-4-yl)-2-(4-henoxyphenyl)nicotinamide

Also Published As

Publication number Publication date
UY37316A (en) 2018-01-31
WO2018007556A1 (en) 2018-01-11

Similar Documents

Publication Publication Date Title
US20140348917A1 (en) Immediate release formulations and dosage forms of gamma-hydroxybutyrate
JP7458440B2 (en) improved drug formulation
EA025595B1 (en) Pharmaceutical compositions comprising 40-o-(2-hydroxy)ethyl-rapamycin
IL260085A (en) Pharmaceutical compositions comprising phenylaminopyrimidine derivative
JP2010513356A (en) Formulation containing a neurokinin antagonist
ES2932626T3 (en) Pharmaceutical composition comprising Aprepitant and method for its preparation
TW201805003A (en) Pharmaceutical solid dispersion of a BCL-2 inhibitor, pharmaceutical compositions thereof, and uses for the treatment of cancer
KR20220077094A (en) Stability and bioavailability enhanced solid dispersion formulations of Olaparib
JP7378393B2 (en) improved drug formulation
US20170209455A1 (en) Solid Pharmaceutical Composition Comprising PI3K-Inhibitor
US9775832B2 (en) Pharmaceutical composition for oral administration
KR101956586B1 (en) Pharmaceutical composition and preparation method thereof
WO2023195955A1 (en) A film coated tablet comprising selexi̇pag and its preparation process
GR20150100471A (en) Pharmaceutical aprepitant-containing formulation and preparation method thereof